FORTIS-C: A Phase 3, Randomized, Placebo-Controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

FORTIS-C: A Phase 3, Randomized, Placebo-Controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Carboplatin; Paclitaxel; Talactoferrin alfa
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FORTIS-C
  • Most Recent Events

    • 04 Aug 2011 Planned End Date changed from 1 Mar 2013 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 19 May 2009 New source identified and integrated (Agennix media release).
    • 18 Feb 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top